Yanyang Nan

Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLC.

Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLC.

Journal: Biomedicines

Published: March 19, 2026

EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancer.

EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancer.

Journal: Biomaterials

Published: October 30, 2025

Targeting angiopoietin-like protein 3 and interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db/db mice.

Targeting angiopoietin-like protein 3 and interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db/db mice.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: October 23, 2025

ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress.

ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress.

Journal: International journal of biological macromolecules

Published: June 18, 2025

Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models.

Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: October 15, 2024

Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer.

Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer.

Journal: Biomedicines

Published: August 24, 2024

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: August 14, 2024

Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation.

Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation.

Journal: Pharmacological research

Published: August 04, 2024

Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer.

Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 31, 2024

Rubicon siRNA-encapsulated liver-targeting nanoliposome is a promising therapeutic for non-alcoholic fatty liver disease.

Rubicon siRNA-encapsulated liver-targeting nanoliposome is a promising therapeutic for non-alcoholic fatty liver disease.

Journal: International journal of pharmaceutics

Published: July 09, 2024

Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy.

Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy.

Journal: Clinical and translational medicine

Published: May 18, 2024

Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer.

Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer.

Journal: Cell death discovery

Published: April 23, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026